Paula Soteropoulos

Paula has more than 30 years of rare disease biopharma industry experience in strategic and operational leadership areas including drug development, global commercialization, manufacturing, new company formation, and company building. In addition to a strong focus on rare disease, her career spans a broad range of therapeutic areas including cardiovascular and metabolism, neurology, infectious disease, renal, transplant, and oncology. Paula previously served as founding CEO and member of the Board of Directors of Akcea Therapeutics. Prior to Akcea, she was Senior Vice President and General Manager of Cardiometabolic and Rare Disease Businesses and Strategic Alliances at Moderna, Inc. where she led key strategic alliances and built preclinical programs. Before Moderna, Paula spent more than 20 years at Genzyme Corporation where she held positions of increasing responsibility including Vice President and General Manager, Cardiovascular, Rare Diseases. She currently serves as Executive Chairman of Ensoma and as a member of the Board of Directors of uniQure. Paula also serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.

Paula earned both a B.S. in chemical and biochemical engineering and an M.S. in chemical and biochemical engineering from Tufts University, and holds an executive management certificate from the Darden Graduate School of Business at the University of Virginia.